Literature DB >> 10921046

[Expression of vascular endothelial growth factor correlates with invasion and metastasis of hepatocellular carcinoma].

X Li1, Z Tang, G Zhou.   

Abstract

OBJECTIVE: To study the relationship between the expression of vascular endothelial growth factor (VEGF) mRNA and invasion and metastasis of hepatocellular carcinoma (HCC), and explore new approaches to prevent and inhibit recurrence and metastasis of HCC.
METHODS: Surgical samples of 43 patients with HCC were studied using reverse transcription-polymerase chain reaction (RT-PCR). The relative level of VEGF mRNA expression was measured by determining a ratio of PCR products of VEGF to that of beta-actin gene.
RESULTS: (1) Expression of VEGF mRNA expression in tumor tissue was found in 79.1% (34/43) of patients, whereas it was seen in 20.9% (9/43) of the nontumorous liver tissue. (2) The level of VEGF mRNA expression in tumors with tumor emboli or in non-encapsulated tumors was higher than that without tumor emboli or in well-encapsulated tumors (P < 0.05). (3) There was no significant difference in the expression of VEGF mRNA between large HCC (diameter > 5 cm) and small HCC (diameter < or = 5 cm) (P > 0.05).
CONCLUSION: VEGF may play an important role in the invasion and metastasis of HCC. Angiogenesis in tumor correlates with the progression of HCC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10921046

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  2 in total

1.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

2.  A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.

Authors:  Jennifer J Knox; Rui Qin; Jonathan R Strosberg; Benjamin Tan; Andreas Kaubisch; Anthony B El-Khoueiry; Tanios S Bekaii-Saab; Steven R Rousey; Helen X Chen; Charles Erlichman
Journal:  Invest New Drugs       Date:  2014-10-16       Impact factor: 3.651

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.